文献速递乳腺癌

细胞周期治疗药物走向成熟

Cell-Cycle Therapeutics Come of Age.
PubMed 文献 · J Clin Oncol · 2017-06-03

本文综述了细胞周期治疗药物的发展,重点介绍了高选择性CDK4/6抑制剂帕博西利、瑞博西利和阿贝西利的作用机制与临床进展。帕博西利和瑞博西利基于无进展生存期改善,已获批联合激素治疗用于初治激素受体阳性晚期乳腺癌。CDK4/6抑制剂单药为细胞静止性且耐受性良好,联合PI3K/mTOR抑制剂或RAS/RAF/MAPK通路抑制剂的研究正在进行,但预测疗效和耐药的生物标志物仍 largely 未明确。

要点

  • 帕博西利和瑞博西利已获批联合激素治疗用于初治激素受体阳性晚期乳腺癌。
  • CDK4/6抑制剂单药为细胞静止性,耐受性良好,促进了联合治疗探索。
  • 预测CDK4/6抑制剂反应和耐药的生物标志物仍 largely 未明确。

核心结论

  • CDK4/6抑制剂已成为最有前景的细胞周期治疗药物,目前正大力拓展该范式的应用范围。

研究设计与样本

  • 本文为综述,检索范围原文未报告。

主要发现

  • 第一代CDK抑制剂对多种CDK有广泛活性,可能解释其较大毒性和有限疗效。
  • 帕博西利、瑞博西利和阿贝西利是新型高特异性ATP竞争性CDK4/6抑制剂,在视网膜母细胞瘤蛋白阳性肿瘤模型中诱导可逆的G1期细胞周期停滞。
  • 帕博西利和瑞博西利基于无进展生存期改善,已获批联合激素治疗用于初治激素受体阳性晚期乳腺癌。
  • CDK4/6抑制剂单药一般为细胞静止性,但表现出良好的耐受性,促使了联合治疗的兴趣。
  • 与磷脂酰肌醇3-激酶和哺乳动物雷帕霉素靶蛋白抑制剂联合用于乳腺癌,以及与RAS/RAF/丝裂原活化蛋白激酶通路抑制剂联合用于RAS突变癌症,是尤其有前景且正在评估的方法。

关键数值与推荐

  • 原文未报告具体数值标准。

临床怎么用

  • 帕博西利和瑞博西利联合激素治疗已获批用于初治激素受体阳性晚期乳腺癌。
  • CDK4/6抑制剂单药为细胞静止性且耐受性良好,联合PI3K/mTOR抑制剂或RAS/RAF/MAPK通路抑制剂的研究正在进行。

局限性

  • 预测CDK4/6抑制剂反应和耐药的生物标志物仍 largely 未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The ability to sustain unscheduled proliferation is a hallmark of cancer. The normal process of cell division occurs via the cell cycle, a series of highly regulated steps that are orchestrated at the molecular level by specific cyclins that act in association with cyclin-dependent kinases (CDKs). Cyclin D and CDK4/6 play a key role in cell-cycle progression by phosphorylating and inactivating the retinoblastoma protein, a tumor suppressor that restrains G1- to S-phase progression. The first-generation CDK inhibitors demonstrated broad activity upon several CDKs, which likely explains their considerable toxicities and limited efficacy. Palbociclib, ribociclib, and abemaciclib represent a new class of highly specific ATP-competitive CDK4/6 inhibitors that induce reversible G1-phase cell-cycle arrest in retinoblastoma-positive tumor models. Both palbociclib and ribociclib have been approved in combination with hormone-based therapy for the treatment of naïve hormone receptor-positive advanced breast cancer on the basis of an improvement in progression-free survival. In general, CDK4/6 inhibitors are cytostatic as monotherapy but demonstrate favorable tolerability, which has prompted interest in combination approaches. Combinations with phosphatidylinositol 3-kinase and mammalian target of rapamycin inhibitors in breast cancer, and inhibitors of the RAS/RAF/mitogen-activated protein kinase pathway in RAS-mutant cancers are particularly promising approaches that are currently being evaluated. Although the subject of intense preclinical study, predictive biomarkers for response and resistance to these drugs remain largely undefined. CDK4/6 inhibitors have emerged as the most promising of the cell-cycle therapeutics and intense efforts are now underway to expand the reach of this paradigm.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ingham M, Schwartz GK. Cell-Cycle Therapeutics Come of Age. J Clin Oncol. 2017. PMID: 28580868. doi:10.1200/JCO.2016.69.0032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。